Skip to content

Study · Randomized controlled trial · n = 58 · 2012

4 results

Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.

Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson GC 3rd and 6 more

Show all authors

Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA

The Journal of clinical endocrinology and metabolism14 Jun 2012Cited by 59 (Europe PMC)

PMID22701017 (opens in a new tab)DOI10.1210/jc.2012-1262 (opens in a new tab)PepBankPUB-22701017
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide produced higher mineralizing surface/bone surface than zoledronic acid.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide produced more active bone-forming surface than zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMineralizing surface/bone surface at month 6
    Study

    n = 58

    Comparator
    Zoledronic acid
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Median MS/BS
    5.6%
    teriparatide
    Median MS/BS
    0.16%
    zoledronic acid

    Source sentences

    Summary
    Among 58 subjects with evaluable biopsies (TPTD = 28; ZOL = 30), MS/BS was significantly higher in the TPTD group (median: 5.60 vs. 0.16%, P < 0.001).
    4 context sentences
    Summary · context
    This was a 12-month, randomized, double-blind, active-comparator controlled, cross-sectional biopsy study.
    Summary · context
    Healthy postmenopausal women with osteoporosis participated in the study.
    Summary · context
    Subjects received TPTD 20 μg once daily by sc injection (n = 34) or ZOL 5 mg by iv infusion at baseline (n = 35).
    Summary · context
    The primary end point was mineralizing surface/bone surface (MS/BS), a dynamic measure of bone formation, at month 6.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, mineral apposition rate was higher with teriparatide than with zoledronic acid.

    In plain wordsIn postmenopausal women with osteoporosis, bone mineral deposition was faster with teriparatide than with zoledronic acid.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMineral apposition rate
    Study

    n = 58

    Comparator
    Zoledronic acid
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Other bone formation indices, including MAR, were also higher in the TPTD group (P < 0.05).
    3 context sentences
    Summary · context
    This was a 12-month, randomized, double-blind, active-comparator controlled, cross-sectional biopsy study.
    Summary · context
    Healthy postmenopausal women with osteoporosis participated in the study.
    Summary · context
    Subjects received TPTD 20 μg once daily by sc injection (n = 34) or ZOL 5 mg by iv infusion at baseline (n = 35).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide significantly increased PINP at the reported assessment months.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide increased a blood marker of bone formation compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP at months 1, 3, 6, and 12
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD significantly increased procollagen type 1 N-terminal propeptide (PINP) at months 1, 3, 6, and 12 and carboxyterminal cross-linking telopeptide of collagen type 1 (CTX) from months 3 to 12.
    3 context sentences
    Summary · context
    This was a 12-month, randomized, double-blind, active-comparator controlled, cross-sectional biopsy study.
    Summary · context
    Healthy postmenopausal women with osteoporosis participated in the study.
    Summary · context
    Subjects received TPTD 20 μg once daily by sc injection (n = 34) or ZOL 5 mg by iv infusion at baseline (n = 35).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, teriparatide significantly increased CTX during the reported interval.

    In plain wordsIn postmenopausal women with osteoporosis, teriparatide increased a blood marker of bone breakdown compared with baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCTX from months 3 to 12
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    TPTD significantly increased procollagen type 1 N-terminal propeptide (PINP) at months 1, 3, 6, and 12 and carboxyterminal cross-linking telopeptide of collagen type 1 (CTX) from months 3 to 12.
    3 context sentences
    Summary · context
    This was a 12-month, randomized, double-blind, active-comparator controlled, cross-sectional biopsy study.
    Summary · context
    Healthy postmenopausal women with osteoporosis participated in the study.
    Summary · context
    Subjects received TPTD 20 μg once daily by sc injection (n = 34) or ZOL 5 mg by iv infusion at baseline (n = 35).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.